Answers are grounded in this paper and cite their sources.
Findings demonstrate circulating tumor DNA effectively detects mutations in non-small cell lung cancer, suggesting its utility when tissue biopsy is impractical.
mutation detection in patients with NSCLC, particularly those with advanced-stage disease. These findings support ctDNA as a viable alternative for molecular profiling in settings where tissue biopsy is limited or impractical.
No takes yet. Share an insight, caveat, or question.
Soroar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: